Skip to main content
Fig. 4 | BMC Gastroenterology

Fig. 4

From: Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn’s disease patients: a German retrospective chart review

Fig. 4

Duration of treatment outcomes by index treatment. Kaplan-Meier analysis of the duration of treatment outcomes in patients with ulcerative colitis (panels a-c) or Crohn’s disease (panels d-f) by index treatment (vedolizumab vs anti-tumor necrosis factor alpha [anti-TNFα])

Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us